GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CTI BioPharma Corp (FRA:CEPS) » Definitions » Float Percentage Of Total Shares Outstanding

CTI BioPharma (FRA:CEPS) Float Percentage Of Total Shares Outstanding : 56.33% (As of Jun. 19, 2024)


View and export this data going back to 2007. Start your Free Trial

What is CTI BioPharma Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, CTI BioPharma's float shares is 74.28 Mil. CTI BioPharma's total shares outstanding is 131.88 Mil. CTI BioPharma's float percentage of total shares outstanding is 56.33%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, CTI BioPharma's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, CTI BioPharma's Institutional Ownership is 31.83%.

CTI BioPharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

CTI BioPharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=74.28/131.88
=56.33%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CTI BioPharma (FRA:CEPS) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CTI BioPharma Corp (FRA:CEPS) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
TVTX IRON IBRX KROS PLRX VERV INBX LGND MLTX KYMR OCSE:NOVO B ASX:CSL VRTX REGN MRNA XKRX:207940 SGEN BNTX OCSE:GMAB ALNY
Traded in Other Exchanges
N/A
Address
3101 Western Avenue, Suite 800, Seattle, WA, USA, 98121
Website
https://www.ctibiopharma.com
CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under the pipeline include Pacritinib. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.

CTI BioPharma (FRA:CEPS) Headlines

No Headlines